Do you feel that HDR brachytherapy alone is adequate treatment for some intermediate-risk prostate cancer patients?

Based upon a nearly 300 patient retrospective analysis of intermediate-risk prostate cancer patients at GammaWest Cancer Services, the answer appears to be a simple "yes," and for nearly all intermediate-risk patients. We published this in the Journal of Urology in 2012, and did not intend to select...

Dose to the prostate is critical for successful management of localized intermediate risk prostate cancer, and HDR brachytherapy can't be beat in this regard. There is a growing body of literature to support this approach.